PMI vs. WHO: The Battle for the Narrative on Safer Nicotine

In 2024, Philip Morris International published a full-page advertisement in major newspapers across 15 countries with a startling headline: 'The World Health Organization is failing one billion smokers.' The ad accused the WHO of 'ignoring science' and 'denying smokers access to better alternatives.' The same week, the WHO issued a statement denouncing tobacco industry 'disinformation campaigns' and reaffirming its position that all tobacco products are harmful. The exchange was the latest salvo in a propaganda war that has been intensifying for years—a battle not over specific policies but over the fundamental narrative: is the rapid transition to non-combustible nicotine products a public health breakthrough or a tobacco industry trap? The question would be academic if the stakes weren't so high. The narrative that prevails will shape regulation, taxation, public perception, and ultimately mortality for hundreds of millions of people.

PMI's narrative strategy is sophisticated, well-funded, and audacious in its scope. The company has positioned itself not as a tobacco company defending cigarettes but as a technology company disrupting them—a transformation narrative that borrows heavily from the Silicon Valley playbook of 'creative destruction.' The messaging is consistent across channels: cigarettes are a 'relic of the past'; the future is 'smoke-free'; smokers 'deserve access to better alternatives.' The company publishes a 'PMI Science' website, funds research through its Foundation for a Smoke-Free World (recently rebranded and restructured after sustained criticism of its industry ties), and deploys an army of PR professionals, lobbyists, and third-party allies to amplify its message. The strategy's genius is that much of what it says is factually true—non-combustible products ARE less harmful than cigarettes—while strategically omitting the context that makes those facts less exculpatory than PMI would like: the company still sells 600 billion cigarettes annually, continues to fight tobacco control measures globally, and has a documented history of scientific deception.

The WHO's counter-narrative is rooted in institutional memory and the precautionary principle. The organization remembers that every previous 'safer cigarette' claim—filters, low-tar, light—was a marketing deception that increased harm by discouraging cessation. It sees the same industry that perpetrated those deceptions now promoting the current generation of 'safer' products. It notes that long-term health effects of these products are unknown, that dual use (rather than complete switching) is common, and that youth initiation through these products is a real and growing problem. And it invokes Article 5.3 of the FCTC, which treats the tobacco industry as an irreconcilable adversary whose interests are fundamentally opposed to public health. The WHO's position has the weight of moral authority and institutional credibility. But it also has a tactical vulnerability: its blanket rejection of harm reduction claims, including those supported by independent research, makes it appear ideologically rigid to audiences who don't share its institutional history or precautionary commitments.

The Foundation for a Smoke-Free World represents a particularly contentious chapter in the narrative war. Founded in 2017 with nearly $1 billion in funding from PMI, the Foundation positioned itself as an independent research organization dedicated to reducing smoking-related harm. Public health organizations almost universally rejected it, citing its industry funding as an irremediable conflict of interest, and the WHO issued a statement urging governments and researchers not to engage with it. The Foundation funded research, convened conferences, and published papers—some critical of the tobacco industry, many supportive of harm reduction—while struggling to establish credibility independent of its funder. In 2023, the Foundation announced it would phase out PMI funding and seek alternative support, a move widely interpreted as an acknowledgment that the industry taint was insurmountable. The Foundation's arc illustrates the core dilemma of industry-funded health research: even when the science is sound, the funding source poisons its reception.

The narrative war is fought not just in newspapers and academic journals but in the regulatory trenches where specific decisions are made. When the FDA evaluates a PMI application for a modified-risk designation, the institutional memory of the industry's deception is a factor—not an explicit regulatory criterion, but an inescapable backdrop that shapes how evidence is interpreted and how much benefit of the doubt the applicant receives. When the WHO's Conference of the Parties debates the classification of novel nicotine products, the same dynamic plays out at the international level. The industry's history means that the same evidence—a toxicological study showing reduced exposure, an epidemiological analysis showing switching patterns—is interpreted more skeptically when the industry is the source than when independent researchers produce similar findings. This is arguably rational: the industry has forfeited the presumption of good faith. But it also means that evidence is being evaluated partly on its source rather than its merits, which is a problem for evidence-based policymaking.

Independent researchers are caught in the crossfire. A scientist who publishes a study finding that e-cigarettes help smokers quit may find their work cited approvingly by PMI and dismissed by the WHO as 'industry-influenced' even if the funding was entirely governmental. A researcher who publishes findings critical of vaping may find their work amplified by the WHO and attacked by harm-reduction advocates as 'prohibitionist.' The polarization of the field has created an environment where the middle ground—'e-cigarettes are probably less harmful than cigarettes but not harmless, and the net population effect depends on regulatory context'—is largely uninhabitable. Researchers who try to occupy that ground are claimed by both sides for their supportive findings and attacked by both sides for their critical ones. The result is a scientific discourse that's been deformed by the political battle it's embedded in.

The resolution of the PMI vs. WHO narrative war won't come from better evidence—the evidence on most key questions is already substantial, and what's needed is longitudinal data that will take decades to accumulate regardless. It will come from institutional and structural changes that address the underlying trust deficit. For the industry, that means subjecting its products and claims to genuinely independent scrutiny—not funding arms-length foundations or publishing self-sponsored research, but accepting the same regulatory standards for transparency, pre-registration, and data sharing that pharmaceutical companies must meet. For the WHO, that means engaging more directly with the evidence for harm reduction, acknowledging where the data supports reduced-risk claims even when the messenger is tainted, and developing regulatory pathways that distinguish between products based on their risk profiles rather than their manufacturers. Both of these are unlikely in the short term. The narrative war will continue—in newspapers, in regulatory hearings, in the minds of smokers trying to decide whether to switch. And while it continues, the question of whether non-combustible nicotine products represent a public health breakthrough or a industry trap will remain unresolved—not because the evidence can't answer it, but because the institutions that could resolve it are too invested in the conflict to try.